Invivyd Launches Phase 3 Trial for VYD2311 mAb COVID Prevention
Topline data from the randomized, double-blind LIBERTY study is expected in Q3 2026, alongside results from the pivotal…
Topline data from the randomized, double-blind LIBERTY study is expected in Q3 2026, alongside results from the pivotal…
Fast Track status shortens FDA review timelines for serious conditions with unmet need — a designation increasingly rel…
Exosome-based delivery systems are emerging as a next-generation carrier technology; analytical validation could reshap…
The Cambridge-Boston biopharmaceutical firm signals a governance upgrade as it pushes first-in-class candidates toward …
The clinic entry marks a milestone for epigenetic reprogramming as a mechanism in age-related optic neuropathy — a cate…
As AI penetrates clinical workflows, supplement and functional food manufacturers face pressure to adopt similar tools …
The phase 3 trial tests a precision medicine approach to DED — a category where nutraceutical and Rx crossover is inten…
The Basel-based biotech's move signals growing crossover between nutraceutical-adjacent pathway science and clinical ne…
The artisan bagel chain's Southeast push reflects sustained consumer demand for premium, craft-positioned bakery format…
Functional News covers ingredient science, clinical nutrition, regulatory affairs, and the functional food and suppleme…
Functional News covers ingredient science, finished formulations, regulatory affairs, and operator strategy — not legal…
Functional News covers ingredient science, finished formulations, regulatory affairs, and market intelligence for the f…